Showing 19,861 - 19,880 results of 102,546 for search '(( 50 ((ng decrease) OR (((teer decrease) OR (mean decrease)))) ) OR ( 5 a decrease ))', query time: 1.35s Refine Results
  1. 19861

    Structural and Co-conformational Effects of Alkyne-Derived Subunits in Charged Donor−Acceptor [2]Catenanes by Ognjen Š. Miljanić (2485972)

    Published 2007
    “…The barriers for the three processes were found to be successively 14.4, 14.5−17.5, and 13.1−15.8 kcal mol<sup>-1</sup>. Within the limitations of the small dataset investigated, emergent trends in the barrier heights can be recognized:  the values decrease with the increasing size of the π-electron-donating macrocycle and tend to be lower in the sterically less encumbered series of [2]catenanes containing the 1,3-butadiyne moiety.…”
  2. 19862

    Effect of Substituents on the Water Oxidation Activity of [Ru<sup>II</sup>(terpy)(phen)Cl]<sup>+</sup> Procatalysts by Dakshika C. Wanniarachchi (1824820)

    Published 2014
    “…A series of [Ru<sup>II</sup>(terpy-R)­(phen-X)­Cl]­PF<sub>6</sub> complexes was designed where terpy-R is the tridentate 4′-(4-methylmercaptophenyl)-2,2′:6′2″-terpyridine ligand MeMPTP and phen-X is a substituted phenanthroline with hydro (<b>1</b>), 5-nitro (<b>2</b>), 5,6-dimethyl (<b>3</b>), and 3,4,7,8-tetramethyl (<b>4</b>). …”
  3. 19863

    Effect of Substituents on the Water Oxidation Activity of [Ru<sup>II</sup>(terpy)(phen)Cl]<sup>+</sup> Procatalysts by Dakshika C. Wanniarachchi (1824820)

    Published 2014
    “…A series of [Ru<sup>II</sup>(terpy-R)­(phen-X)­Cl]­PF<sub>6</sub> complexes was designed where terpy-R is the tridentate 4′-(4-methylmercaptophenyl)-2,2′:6′2″-terpyridine ligand MeMPTP and phen-X is a substituted phenanthroline with hydro (<b>1</b>), 5-nitro (<b>2</b>), 5,6-dimethyl (<b>3</b>), and 3,4,7,8-tetramethyl (<b>4</b>). …”
  4. 19864
  5. 19865
  6. 19866
  7. 19867
  8. 19868
  9. 19869
  10. 19870

    Spectral-domain optical coherence tomography (SD-OCT) images taken from a 72-year-old female patient with neovascular age-related macular degeneration (nAMD) who received ranibizum... by Zheyao Gu (20910794)

    Published 2025
    “…However, the patient’s treatment was interrupted for 3.5 months because of the COVID-19 lockdown. When the patient returned for treatment, the BCVA had decreased to 0.73 (logMAR); the corresponding OCT image taken at V1 (C) shows subretinal hemorrhage, IRF and SRF. …”
  11. 19871

    Data_Sheet_1_Growth of freshwater cyanobacterium Aphanizomenon sp. ULC602 in different growing and nutrient conditions.docx by Mai-Lan Pham (17686353)

    Published 2023
    “…Moreover, a decrease in Chlo-a biomass was observed under sulfur deficiency. …”
  12. 19872
  13. 19873
  14. 19874

    Table 1_Eculizumab is efficacious and safe in pediatric patients with various forms of hemolytic uremic syndrome: a retrospective clinical experience of a tertiary center.docx by Naama Lax (20998004)

    Published 2025
    “…</p>Results<p>Twenty-four pediatric patients (median age 5.8 years) were included: 13 with aHUS, 5 with STEC-HUS, and 6 with TA-TMA. …”
  15. 19875

    Table_1_Effectiveness, Healthcare Resource Utilization and Adherence to Subcutaneous Interferon Beta-1a According to Age in Patients With Multiple Sclerosis: A Cohort Study Using a... by Arthur Allignol (4017428)

    Published 2021
    “…</p><p>Results: Of the 5,340 patients included in the analysis, there was a high proportion of patients free from relapse across all age groups (range: 94.1–95.4%), with a numerical decrease in the number of MRI performed by age (mean: 0.25, 18–30 years; 0.20, 31–40 years; 0.16, 41–50 years; 0.14, ≥51 years). …”
  16. 19876

    Table_1_Effectiveness, Healthcare Resource Utilization and Adherence to Subcutaneous Interferon Beta-1a According to Age in Patients With Multiple Sclerosis: A Cohort Study Using a... by Arthur Allignol (4017428)

    Published 2021
    “…</p><p>Results: Of the 5,340 patients included in the analysis, there was a high proportion of patients free from relapse across all age groups (range: 94.1–95.4%), with a numerical decrease in the number of MRI performed by age (mean: 0.25, 18–30 years; 0.20, 31–40 years; 0.16, 41–50 years; 0.14, ≥51 years). …”
  17. 19877
  18. 19878
  19. 19879
  20. 19880